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A B S T R A C T
The presence of side effects during pharmacological treatment is unfortunately a quite common problem. In this
review, we focused our attention on adverse events related to 5 alpha-reductase (5α-R) inhibitors (i.e., finas-
teride and dutasteride), approved for the treatment of benign prostatic hyperplasia and androgenetic alopecia
(AGA).
Although these drugs are generally well tolerated, many reports described adverse effects in men during
treatment, such as sexual dysfunction and mood alteration. In addition, it has been also reported that persistent
side effects may occur in some AGA patients. This condition, termed post-finasteride syndrome (PFS) is char-
acterized by sexual side effects (i.e., low libido, erectile dysfunction, decreased arousal and difficulty in
achieving orgasm), depression, anxiety and cognitive complaints that are still present despite drug withdrawal.
Indeed, some national agencies (e.g., Swedish Medical Products Agency, the Medicines and Healthcare Products
Regulatory Agency of UK and the U.S. Food and Drug Administration) required to include multiple persistent
side effects within the finasteride labels.
As here reported, these observations are mainly based on self-reporting of the symptomatology by the patients
and few clinical studies have been performed so far. In addition, molecular mechanisms and/or genetic de-
terminants behind such adverse effects have been poorly explored both in patients and animal models.
Therefore, results here discussed indicate that PFS is an emerging clinical problem that needs to be further
elucidated.
1. Introduction
The enzyme 5alpha-reductase (5α-R) exerts a key role in the acti-
vation of neuroactive steroids, such as testosterone (T) and proges-
terone (PROG). Indeed, T and PROG are metabolized by 5α-R into di-
hydrotestosterone (DHT) and dihydroprogesterone (DHP), respectively.
These neuroactive steroids (i.e., steroids synthesized from peripheral
glands as well as directly in the nervous system) are then further con-
verted by the action of 3α-hydroxysteroid oxidoreductase (3α-HSOR)
or 3β-hydroxysteroid oxidoreductase (3β-HSOR) into further metabo-
lites, such as 5α-androstane-3α,17β-diol (3α-diol) or 5α-androstane-
3β,17β-diol (3β-diol) in case of DHT and tetrahydroprogesterone (THP,
also known as allopregnanolone) or isopregnanolone in case of DHP. All
these neuroactive steroids, together with their precursors (i.e., preg-
nenolone, PREG, and dehydroepiandrosterone, DHEA) interacting with
classical (e.g., progesterone, PR, androgen, AR, and estrogen receptors,
ER) and non-classical (e.g. neurotransmitter and membrane steroid
receptors) steroid receptors represent important physiological mod-
ulators of the nervous function (Giatti et al., 2019; Melcangi et al.,
2016). As reported in Fig. 1, finasteride (e.g., Propecia or Proscar) is an
inhibitor of two isoforms of the 5α-R (i.e., type 1 and 2), although it has
higher affinity for the type 2 in humans (Finn et al., 2006; Traish et al.,
2015). This drug, proved to be highly effective in the control of DHT
levels and of the progression of benign prostatic hyperplasia (BPH), was
approved for this use in 1992. This inhibitor was then, in 1997, ap-
proved for the treatment of androgenetic alopecia (AGA). Finasteride at
1 mg/day has been shown to lead to a significant reduction in the
progression of the baldness and to a stimulation of new hair growth
(Kaufman et al., 1998). Dutasteride (e.g., Avodart) inhibits both 5α-R
type 1 and 2 (Fig. 1) with greater potency than finasteride (Frye et al.,
1998), and has similar efficacy to this latter drug on BPH symptoms.
5α-R inhibitors have generally been described as well-tolerated and
relatively safe drugs; however, recent observations have led to a more
critical re-evaluation of these concepts. Indeed, as will be here dis-
cussed, 5α-R inhibitors not only induced side effects during the treat-
ment, but, as reported in case of finasteride, they may also persist after
drug discontinuation inducing the so called post-finasteride syndrome
(PFS).
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1.1. Side effects of 5α-reductase inhibitors and post-finasteride syndrome:
what patients tell us
Finasteride or dutasteride treatment has been associated with the
onset of different side effects. Mainly, the affected domains are related
to sexual function. Indeed, sexual adverse events (AEs) in BPH patients
treated with finasteride (Bruskewitz et al., 1999; Edwards and Moore,
2002; Fwu et al., 2014; Marberger, 1998; Nickel et al., 1996; Traish
et al., 2015; Wilton et al., 1996) or dutasteride (Clark et al., 2004;
Desgrandchamps et al., 2006; Kaplan et al., 2012; Roehrborn et al.,
2002) have been reported. Moreover, observational studies as well as
clinical reports indicated similar complaints in male subjects treated
with these inhibitors for AGA (Belknap et al., 2015; Choi et al., 2016;
Kaufman et al., 1998; Tsunemi et al., 2016). Indeed, analyzing the
American Food and Drug Administration Adverse Event Reporting
System (FAERS), Gupta and collaborators reported an increased risk to
develop sexual dysfunction with finasteride (Gupta et al., 2017) or
dutasteride (Gupta et al., 2018) use in comparison to the baseline risk
assessed for all the other drugs. More recently, FAERS database was also
queried in order to evaluate which cluster of symptoms have been de-
scribed after finasteride use at the dose of 1 mg (to treat alopecia) and
5 mg (to treat BPH). Baas and colleagues identified three main areas of
AEs, classified as sexual, psychological and physical domains (Baas
et al., 2018). In all domains, a significant higher number of cases were
present in patients treated with finasteride at the lower dose (1 mg) in
comparison to those with the higher dose (5 mg). In particular, within
the sexual domain, an increased sexual dysfunction, decreased or loss of
libido, disorders of ejaculation, erectile dysfunction, testicular atrophy,
orgasmic disorders and hypogonadism were reported by 1 mg finas-
teride users, while in the psychological domain, the same dose was
associated to an increased self-harm, slow cognition, psychological
pathology, change in emotional affect and sleep disturbances, com-
pared to the higher dose. Finally, regarding the physical domain, sig-
nificantly increased reports about skin rush and metabolic abnormal-
ities were indicated by low dose finasteride users. In addition,
gynecomastia was more frequently reported by 5 mg finasteride users,
although this increase was not statistically significant (Baas et al.,
2018). Interestingly, Motofei and colleagues reported differences in
sexual complains between right-handed and left-handed subjects taking
finasteride, suggesting that lateralization of functions might be relevant
in these processes (Motofei et al., 2013, 2016, 2017). In particular,
right-handed users presented an overall decreased International Index
of Erectile Function (IIEF) score compared to the left-handed users, that
have, on the other side, an improved orgasmic function compared to the
right-handed finasteride users (Motofei et al., 2013, 2016, 2017). In
contrast with these findings, Haber and collaborators reported no
sexual dysfunction associated to finasteride treatment for alopecia in a
single-centre, controlled study of 762 subjects (Haber et al., 2019). In
addition, other reports, including randomized studies, showed no in-
cidence of sexual impairment after finasteride use (Liu et al., 2016;
Narasimhalu, 2015; Tosti et al., 2001, 2004).
Overall, these results indicate no consensus with respect to the
presence of sexual side effects during treatment with 5α-R inhibitors.
However, recent observations also demonstrated that, in case of
AGA, side effects associated with finasteride may also persist despite
the drug suspension (i.e., inducing the PFS). Indeed, Irwig and Kolukula
interviewed 71 subjects who reported sexual dysfunction despite they
stopped finasteride use by at least three months (Irwig and Kolukula,
2011). They described low libido, erectile dysfunction, decreased
arousal and difficulty in achieving an orgasm (Irwig and Kolukula,
2011). Interestingly, these adverse events did not resolve in the ma-
jority of subjects after 9 and 16 months of withdrawal from the drug
(Irwig, 2012b). Another report collected 131 web-based surveys of
patients lamenting new symptoms onset after finasteride use. Subjects
were recruited from those seeking medical help after treatment or
visiting Propeciahelp.com website (Ganzer et al., 2015). Authors di-
vided symptoms collected from patients in five categories: physical,
sexual libido, disorder of penis and testes, cognitive disorders and
psychological disorders. From each category, the higher percentage of
cases regarded: gynecomastia (70% of cases in physical category), de-
creased sex drive (93% of cases in sexual libido category), diminished
semen volume and force (82% of cases in disorder of penis and testes
category), mental cloudiness or brain fog (75% of cases in cognitive
disorders category) and elevated anxiety (74% of cases in psychological
disorders category) (Ganzer et al., 2015). This survey also highlighted
the high number of subjects reporting suicidal ideation (63%), due to
the negative thoughts and the inability to live a life with such symptoms
(Ganzer et al., 2015). This latter result was in line with previous find-
ings (Irwig, 2012a).
Observations based on a recent questionnaire-based survey per-
formed in 54 PFS patients have been also published (Giatti et al., 2018).
As shown, 22% of patients reported lack of connection between the
brain and penis during treatment, and this percentage increased to 59%
at interview time (i.e., at least three months after finasteride dis-
continuation). This side effect was not reported by the patients before
the finasteride treatment. Similarly, the loss of libido and sex drive was
reported in 24% of the patients during treatment and increased to 56%
at interview time. This side effect was reported in 4% of patients before
the treatment. Difficulty in achieving an erection was reported in 17%
of patients during inhibitor administration and increased to 61% at
interview time. Finally, genital numbness or paresthesia was reported
in 17% of patients during treatment and increased to 37% of cases at
interview time (Giatti et al., 2018). Beside sexual problems, PFS pa-
tients also reported psychological complaints (such as decreased self-
confidence, irritability or easily flying into a rage, nervousness, agita-
tion, inner restlessness, depression, hopelessness, feelings of worth-
lessness, suicidal thoughts, anxiety, panic attacks, sleep problems),
muscular problems (tics, muscle spasms and fasciculation, tremors,
involuntary muscle tension and contraction, chronic fatigue, weakness,
ataxia, joint pain and muscular ache), physical alterations (dizziness,
headache, migraine, head pressure, decreased body temperature) and
cognitive complains (decreased initiative and difficulty in concentra-
tion, mental confusion, forgetfulness or loss of short-term memory,
losing train of thought or reasoning, slurred speech or stumbling over
words) (Melcangi et al., 2017).
“Propeciahelp.com” forum has been also considered as a source.
Indeed, Walf and colleagues analyzed 224 discussions on this web site
and collected self-reported symptoms of PFS patients (Walf et al.,
2018). The symptoms were divided into four categories: anti-andro-
genic effects (such as demasculinizing events consequent to DHT de-
privation on sexual organs), estrogenic effects (i.e., feminizing features
related to the increased aromatization of testosterone), central/brain
effects (linked to the alteration of neurosteroid synthesis and
Fig. 1. Metabolism of progesterone and testosterone into 5alpha-reduced me-
tabolites and their mechanisms of action: effects of finasteride and dutasteride.
AR: androgen receptor; DHP: dihydroprogesterone; DHT: dihydrotestosterone;
ERβ: estrogen receptor beta; PR: progesterone receptor; PROG: progesterone; T:
testosterone; THP: tetrahydroprogesterone.
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metabolism or to thromboembolitic events) and, finally, nonspecific/
severe AEs (collecting other severe effects that could not be classified in
the above categories but are considered serious) (Walf et al., 2018). The
analysis indicated antiandrogenic effects in the 32%, central effects in
the 30%, estrogenic effects in the 19%, and nonspecific/severe AEs in
the 5% of cases (Walf et al., 2018).
Persistent sexual side effects possibly due to finasteride treatment
have been also analyzed by Healy and colleagues based on the self-
reported alerts into the RxISK.org website (i.e., an independent drug
safety website aiming to collect data on all drug-related AEs) (Healy
et al., 2018). A total of 24 male subjects completed the report indicating
different symptoms related to sexual functions that persisted after fi-
nasteride use. In line with previous reports, 92% of patients claimed
erectile dysfunction and loss of libido, 44% genital anesthesia and 32%
watery ejaculation and testicular atrophy. In this survey, other in-
frequent symptoms, such as reduced sense of taste (8%) and of smell
(4%), were reported (Healy et al., 2018).
Criticism about the existence of PFS has been also raised. In parti-
cular, subject selection in the study design, lack of adequate control
groups, possible nocebo effect and the use of retrospective ques-
tionnaires may introduce important biases, leading to poor quality of
the studies performed (Baas et al., 2018; Haber et al., 2019; Mondaini
et al., 2007).
Nevertheless, it is important to highlight that the so called PFS is a
rare condition, that could be not adequately investigated in larger co-
hort studies. In particular, many of these studies lack of long follow-up
of patients, and specific symptoms (e.g., sexual dysfunction or psy-
chological problems) may not be investigated in detail (Belknap et al.,
2015). On the other hand, objective measurements and deeper clinical
assessments are imperative to describe PFS symptomatology.
1.2. What has been so far clinically demonstrated about the existence of
PFS
As mentioned in section 2.1, the observations present in literature
are mainly based on symptoms self-reported by patients. Indeed, only
few papers have rigorously investigated these aspects so far (Fig. 2). In
this context, one of the markers taken in consideration has been the
levels of neuroactive steroids in PFS patients. The rational was based on
the following reasons: 1) finasteride is able to block a fundamental step
in the activation of neuroactive steroids (i.e., 5α-R) (Finn et al., 2006;
Traish et al., 2015); 2) finasteride in AGA patients induced, during
treatment, changes in the plasma levels of neuroactive steroids (i.e.,
decrease in DHT and increase in T and androstenedione) (Duskova
et al., 2010); 3) neuroactive steroids are important key regulators of the
nervous functions (Giatti et al., 2019; Melcangi et al., 2016); 4) some
neuroactive steroids, like for instance THP, isopregnanolone and 3α-
diol are able to modulate GABA-A receptors (Lambert et al., 2003); 5)
altered levels in plasma and cerebrospinal fluid (CSF) of GABA as well
as of neuroactive steroids are associated with depression in several
human studies (Melcangi et al., 2014, 2016; Zorumski et al., 2013). In
addition, a subset of post-finasteride patients with persistent sympto-
matology showed a decline in their alcohol consumption (Irwig, 2013).
This is very interesting, because a relationship between GABAergic
neuroactive steroids and ethanol consumption is well ascertained
(Kumar et al., 2009). On the basis of this rationale, in three different
studies based on three (Melcangi et al., 2013), seven (Caruso et al.,
2015) and fourteen (Melcangi et al., 2017) PFS patients, the plasma and
CSF levels of different neuroactive steroids (i.e., PREG, DHEA, PROG
and its metabolites, T and its metabolites) have been assessed by liquid
chromatography-tandem mass spectrometry. Data obtained indicate
that finasteride treatment has broad consequences on the levels of these
molecules in plasma and particularly in CSF (Caruso et al., 2015;
Melcangi et al., 2013, 2017). Thus, finasteride treatment did not only
affect the 5α-reduced metabolites of PROG and T. Indeed, as observed
in the study with the larger group of patients, lower levels of PREG,
PROG, DHP, DHT and 17β-E and higher levels DHEA, T and 3α-diol
were reported in the CSF of PFS patients in comparison with those
observed in healthy patients (Melcangi et al., 2017). The results ob-
tained in this latter study showed small differences in comparison to the
previous ones (Caruso et al., 2015; Melcangi et al., 2013). This, together
with the presence of a heterogeneous symptomatology, suggests that
PFS patients are not a homogenous pathological group. Interestingly,
the pattern in plasma did not exactly reflect what observed in CSF. For
instance, at variance to what observed in CSF, the plasma levels of
PREG were significantly increased and those of PROG and T metabo-
lites, such as DHT, 3α-diol and 17β-E, were unaffected. In addition, the
levels of THP that were unaffected in CSF, showed a significant de-
creased in plasma. These findings were not surprising because, as de-
monstrated in various physiological or pathological experimental
models, neuroactive steroid changes occurring in plasma did not reflect
exactly what occurs in CSF and in the nervous system (Caruso et al.,
2013; Melcangi et al., 2014, 2016). As demonstrated, not only neu-
roactive steroid levels themselves but also their mechanisms of action
may be altered by finasteride. For instance, an upregulation of AR oc-
curred in the prostate of patients treated with finasteride for BPH
(Hsieh et al., 2011) as well as in the prepuce of AGA patients showing
persistent side effects (i.e., PFS patients) (Di Loreto et al., 2014). In
addition, two polymorphisms in AR gene, (CAG) rs4045402 and (GGN)
rs318869, have been reported to be more frequent among AGA and PFS
patients (Cecchin et al., 2014). As further demonstrated, short and/or
long (CAG)n and (GGN)n repeats in the AR gene have also different
frequencies according to the symptomatology reported by PFS patients
(Cauci et al., 2017).
Epigenetic modifications seem to be also involved (Melcangi et al.,
2019). Indeed, as recently demonstrated, methylation analysis of the
promoter genes coding for type 1 (i.e., SRD5A1) and type 2 (i.e.,
SRD5A2) 5α-R performed in plasma and CSF of 16 PFS patients, in-
dicated that SRD5A2 promoter was more frequently methylated in CSF
of PFS patients compared to healthy controls (56.3% versus 7.7%).
Importantly, this is a tissue-specific methylation. Indeed, SRD5A2 pro-
moter methylation has not been observed in plasma. Interestingly, both
in plasma and CSF, SRD5A1 promoter was not methylated (Melcangi
et al., 2019).
Basaria and coworkers (Basaria et al., 2016) observed impaired
sexual function, assessed by IIEF and Male Sexual Health Questionnaire,
in 25 PFS patients. These observations were confirmed in another study
performed in 16 PFS patients, reporting that 10 of them showed a se-
vere erectile dysfunction, while 6 patients a mild-moderate one
(Melcangi et al., 2017). As demonstrated by ultrasonography scan,
erectile dysfunction in these patients was not associated with altered
testicular volume or alterations in ejaculatory ducts. Interestingly, an
objective evidence of neuropathy involving the peripheral neurogenic
Fig. 2. Clinical features reported in patients affected by post-finasteride syn-
drome. For details, see text. AR: androgen receptor; CSF: cerebrospinal fluid;
MRI: magnetic resonance imaging; SRD5A2: 5 alpha reductase type 2 gene.
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control of erection was reported. Indeed, abnormal somatosensory
evoked potentials of the pudendal nerve were observed in 25% of these
PFS patients (Melcangi et al., 2017).
Depressive symptomatology is related with alteration in neuroactive
steroid levels (Melcangi et al., 2014, 2016; Zorumski et al., 2013). In
addition, the expression levels of 5α-R type 1 enzyme are down-
regulated in prefrontal cortex Brodmamn's area 9 of depressed patients
(Agis-Balboa et al., 2014). Indeed, as reported in two different studies,
using PHQ-9 depression scale, Beck Depression Inventory and Hamilton
Depression Scale 17 (Basaria et al., 2016) or K-10, Mini-International
Neuropsychiatric Interview and Beck Depression and Anxiety In-
ventories (Melcangi et al., 2017), the presence of DSM-IV major de-
pressive disorder was confirmed in PFS patients. Interestingly, func-
tional MRI in PFS patients confirmed abnormalities in brain regions
implicated in depression and sexual arousal, such as nucleus accumbens
and prefrontal cortex (Basaria et al., 2016). In addition, further studies
showed that more than half of the 150 PFS patients considered had a
pre-existing medically confirmed psychiatric diagnosis (Ganzer and
Jacobs, 2016; Ganzer et al., 2015).
1.3. What experimental models tell us
As mentioned in sections 2.1 and 2.2, observations so far obtained
in AGA patients have indicated that both during finasteride treatment
(Duskova et al., 2010) and after its suspension (i.e., in PFS patients)
(Caruso et al., 2015; Melcangi et al., 2013, 2017) the levels of neu-
roactive steroids are affected. Observations obtained in male adult rats
have confirmed these observations (Giatti et al., 2016). Interestingly,
20 days of finasteride treatment and its withdrawal (i.e., one month of
suspension), not only alter the levels of neuroactive steroids in plasma
and CSF, but also those in the central nervous system areas such as
cerebral cortex, cerebellum and hippocampus (Giatti et al., 2016).
Importantly, finasteride treatment differently influenced the neuroac-
tive steroid levels in the brain areas considered. For instance, PROG
levels were increased in the hippocampus but not in the cerebral cortex
and cerebellum. In addition, levels of isopregnanolone and 3α-diol were
increased and decreased respectively in the cerebellum; these changes
did not occur in the cerebral cortex and hippocampus (Giatti et al.,
2016). At the withdrawal, some of the changes observed persisted, such
as the increase in DHP in the cerebellum, and new changes occurred,
such as an increase and a decrease of PREG levels in the cerebellum and
hippocampus, respectively and a decrease of THP in the cerebral cortex.
In addition, T levels were increased while the levels of its metabolite,
DHT, were decreased in the cerebellum (Giatti et al., 2016) (Fig. 3).
Moreover, not only the levels of neuroactive steroids but also the
expression of their receptors, are altered by finasteride treatment in the
brain areas considered. Indeed, an upregulation of AR in rat cerebral
cortex occurred after the chronic treatment as well as at the withdrawal
(Giatti et al., 2016). This is particularly interesting, because it indicates
that the expression of this receptor is not only affected in the periphery,
as observed in AGA patients (Di Loreto et al., 2014), but also in the
nervous system. In addition, the expression levels of one GABA-A sub-
unit, such as the beta 3, were also upregulated in the cerebellum after
finasteride treatment (Giatti et al., 2016). At the withdrawal, an upre-
gulation of the isoform alpha and a downregulation of the isoform beta
of ER were reported in the cerebral cortex. In addition, the expression
of alpha 4 and beta 3 subunits of GABA-A receptors was downregulated
in the cerebral cortex (Giatti et al., 2016).
As mentioned above, depressive symptomatology has been reported
in PFS patients (Basaria et al., 2016; Melcangi et al., 2017). Concerning
observations in animal models, controversial results have been col-
lected so far. For instance, finasteride treatment in adult male rat
showed an increased time of immobility in forced swim test. This effect
occurred after one month of withdrawal, but not immediately after the
treatment (Diviccaro et al., 2019) (Fig. 3). On the contrary, as recently
reported in adult male rats by forced swim test, finasteride
administration induces, immediately after the treatment, a depression-
like phenotype (Sasibhushana et al., 2019). Differences in the experi-
mental protocol, like for instance animal strain (Sprague-Dawley rat vs
Wistar rat), finasteride dose (i.e., 3 mg/kg vs 30 mg/kg), time schedule
(20 days of treatment vs 6 days) might be responsible for this dis-
crepancy of effect.
Interestingly, anhedonia or decreased pleasure-seeking behavior
have been also explored by Sasibhushana and colleagues (Sasibhushana
et al., 2019). Results obtained by the splash test indicate that finasteride
treatment decreased the grooming duration and increased the latency
to groom, which indicates that the drug affected the motivational be-
havior in a negative way (Sasibhushana et al., 2019).
Not only alterations in neuroactive steroid levels (Melcangi et al.,
2014, 2016; Zorumski et al., 2013) but also changes in hippocampal
neurogenesis have been related with depressive-like behaviors
(Santarelli et al., 2003; Snyder et al., 2011). Altered hippocampal
morphology and reduced hippocampal neurogenesis have been also
reported in depressed patients (Hercher et al., 2009; Stockmeier et al.,
2004). Interestingly, 6 days of finasteride administration in male
C57BL/6N mice were able to decrease the hippocampal neurogenesis
(Romer and Gass, 2010; Romer et al., 2010). Recent observations in a
rat model have shown that 20 days of treatment induced a decrease of
granule cell density in the granular layer of the dentate gyrus in rats
showing depressive-like behavior one month after the end of finasteride
treatment (Diviccaro et al., 2019) (Fig. 3).
In humans and experimental models, depression has been demon-
strated to be associated with neuroinflammation (Yirmiya et al., 2015).
Treatment with finasteride also affects this parameter (Fig. 3). Indeed, a
significant increase in the number of astrocytes (i.e., cellular mediators
of the inflammatory response) in the hilus of the dentate gyrus has been
demonstrated one month after the end of the finasteride treatment
(Diviccaro et al., 2019). This effect might be ascribed to the elevated
levels of DHP observed one month after the end of the finasteride
treatment in male rat hippocampus (Giatti et al., 2016). Indeed, in other
experimental models, DHP has been demonstrated to increase GFAP
gene expression in astrocytes (Melcangi et al., 1996). Reactive gliosis is
associated with increased levels of proinflammatory molecules in the
brain (Hostenbach et al., 2014; Wang et al., 2018). In agreement, fi-
nasteride treatment increased, immediately after the treatment, the
expression of TNF-α in male rat hippocampus and, at the withdrawal,
that of IL-1β (Diviccaro et al., 2019). It is important to note that both
cytokines are increased in plasma of depressed patients and in the brain
of animal models for depression (Cheng et al., 2018; Li et al., 2017;
Todorovic and Filipovic, 2017; Wang et al., 2018). Dysregulation of the
dopamine system may also contribute to major depressive disorders
(Belujon and Grace, 2017; Felger, 2017; Grace, 2016). Therefore, in this
context it is important to recall that androgens regulate the dopami-
nergic system in the brain (de Souza Silva et al., 2009; Kindlundh et al.,
2004; Mitchell and Stewart, 1989). Interestingly, finasteride treatment
(25 and 50 mg/kg for 14 days) inhibited open-field behaviors and re-
duced contents of dopamine and its metabolites in central nervous
system (Li et al., 2018). In addition, finasteride treatment was also able
to impair the signaling of dopamine (Devoto et al., 2012; Frau et al.,
2016).
Androgens are also involved in the physiological regulation of
erection. Few preclinical observations have been obtained on the effects
exerted by 5α-R inhibitors. For instance, a 5α-R inhibitor, such as 17
beta-testosterone carboxylic acid, significantly weakened the stimula-
tory effect exerted by T propionate on erection in castrated rats, but not
the mating behavior (Bradshaw et al., 1981). Similarly, another study
performed with finasteride in castrated rats also reported a reduction of
erectile response, although receiving T replacement (Park et al., 1999).
Pinsky and colleagues demonstrated a detrimental effect of dutasteride
on erectile function as well as in the gene expression of nitric oxide
synthase in intact adult male rats (Pinsky et al., 2011). In addition,
another study demonstrated that oral administration of finasteride for
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one month was not able to affect the erectile response to electric sti-
mulation of the cavernous nerve, but resulted in a loss of the weight of
the corpus cavernosum (Zhang et al., 2012). Furthermore, a further
study performed in Wistar–Kyoto adult rats showed that treatment with
finasteride or dutasteride reduced cross-sectional penile area (Da Silva
et al., 2018). In addition, in the same study, dutasteride, but not fi-
nasteride treatment, reduced smooth muscle in the corpus cavernosum
(Da Silva et al., 2018). To our knowledge, only one preclinical study has
explored so far possible persistent erectile dysfunction induced by 5α-R
inhibitors (Sung et al., 2019). In particular, it seems that the recovery
from erectile dysfunction depends on the duration of treatment. Indeed,
after two weeks of withdrawal the erectile dysfunction persisted in rats
treated with dutasteride for more than 8-weeks, but not for 4-weeks
(Sung et al., 2019) (Fig. 3). In this context, it is also important to recall
that, dopamine, a neurotransmitter that, as reported above, is affected
by finasteride treatment (Devoto et al., 2012; Frau et al., 2016; Li et al.,
2018), also modulates male sexual behavior in humans as well as in
animal models (Peeters and Giuliano, 2008; Will et al., 2014).
Finally, as recently demonstrated, finasteride treatment also leads to
kidney damage (Baig et al., 2019) as well as alterations in gut micro-
biota (Diviccaro et al., 2019). Indeed, an experimental study performed
on sexually mature male Wistar rats, confirmed not only that finasteride
treatment altered the steroid hormone levels in plasma, but also the
expression of AR and intracellular junction proteins in the kidney was
impaired (Fig. 3). These alterations are associated with an altered cell
apoptosis/proliferation ratio, and linked to lymphocyte infiltration and
to an increase of IL-6 (Baig et al., 2019). Finasteride treatment is also
able to affect, not only immediately after treatment but also after one
month of discontinuation of the drug, the gut microbiota composition
(Diviccaro et al., 2019). Indeed, immediately after drug treatment an
increase in Bacteroidetes phylum as well as in Prevotellaceae family was
reported; after discontinuation of the finasteride, a decrease in Rumi-
nococcaceae family, Oscillospira and Lachnospira genus was observed
(Diviccaro et al., 2019) (Fig. 3). Changes in gut microbiota could be
ascribed to different factors, such as changes induced by finasteride in
plasma and/or brain neuroactive steroid levels (Giatti et al., 2016).
Indeed, gonadectomy and hormone replacement have a clear effect on
gut bacteria in rodents (Fields et al., 2017; Harada et al., 2016;
Jasarevic et al., 2016; Moreno-Indias et al., 2016; Org et al., 2016; Tetel
et al., 2018; Yurkovetskiy et al., 2013). For instance, Ruminococcaceae
are significantly affected by orchidectomy in mice (Org et al., 2016). In
addition, the existence of a gut microbiota-brain axis has been proposed
(Lerner et al., 2017; Mayer, 2011; Sharon et al., 2016). On the other
hand, although steroidogenesis has not been evaluated in detail in gut
microbiota, intestinal epithelial cells seem to be able to synthesize
glucocorticoids (Cima et al., 2004) and microbial species, like for in-
stance Clostridium scindens, converts glucocorticoids into androgens
(Ridlon et al., 2013). Thus, an alternative possibility is a direct action of
finasteride on gut microbiota. Results obtained on rat gut microbiota
population after finasteride treatment are also interesting since very
similar changes have been observed in patients with major depressive
disorder (Jiang et al., 2015; Lin et al., 2017; Naseribafrouei et al., 2014)
as well as in animal models of depression. For instance, rats with de-
pressive-like behavior show an increase in Bacteroidetes (Yu et al.,
2017).
1.4. What about finasteride therapy and PFS in women?
Finasteride has been approved by the US FDA for the treatment of
alopecia only in male subjects. However, this drug is increasingly used
also in women to treat female pattern hair loss (FPHL) and frontal fi-
brosing alopecia (FFA) (Camacho-Martinez, 2009; Hu et al., 2019).
With particular regard to female alopecia, finasteride is considered
both effective (Boersma et al., 2014; Oliveira-Soares et al., 2013; Won
et al., 2018) and ineffective (Kim et al., 2012; Price et al., 2000; van
Zuuren et al., 2016; Varothai and Bergfeld, 2014). Moreover, indica-
tions for finasteride dosage are confusing. Indeed, studies reporting
dose of 1 mg, 1.25 mg, 2.5 mg or 5 mg have been published (Boersma
et al., 2014; Kim et al., 2012; Mervis et al., 2018; Price et al., 2000).
Also in case of female finasteride users, side effects have been re-
ported during treatment. In particular, Wu and colleagues discussed
information about finasteride side effects in female patients, collected
Fig. 3. Side effects of treatment with 5 alpha-reductase inhibitors in experimental models. For details, see text.
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in the FAERS database (Wu et al., 2016). The top ten AEs reported were:
abortion induction, abortion spontaneous, paternal drug affecting fetus,
uterine cervix stenosis, menstruation irregularity, menorrhagia, en-
dometrial hypertrophy, phalangeal agenesis, fatigue and arthritis (Wu
et al., 2016). Regarding the adverse events on reproductive features, it
is important to recall that finasteride is forbidden in pregnant women,
therefore, careful contraception is strongly suggested during finasteride
treatment.
Other data described, in women treated for alopecia with 5 mg of
finasteride, headache, menstrual irregularities, dizziness and increased
body hair growth as the most common complaints (Shum et al., 2002;
Valsecchi et al., 2004; Yeon et al., 2011). Moreover, decreased libido
and gastrointestinal discomfort were also described (Shum et al., 2002;
Thai and Sinclair, 2002; Valsecchi et al., 2004; Yeon et al., 2011). A
drug-gene network analysis, in patients treated with finasteride, also
revealed that “oocyte meiosis” and “progesterone-mediated oocyte
maturation” pathways were affected by finasteride treatment (Wu et al.,
2016). Few studies evaluated finasteride toxicity in female animal
models. Of note, a paper by Alkahtane and collaborators showed altered
serum biochemical parameters (e.g., alkaline phosphatase, cholesterol,
glucose), increased DNA damage and histological abnormalities in the
liver, spleen, kidney and heart of female Swiss albino mice treated with
finasteride (0.5 or 1.5 mg/kg/day) (Alkahtane et al., 2019) (Fig. 3).
Also in female patients, criticism about the possible side effects in-
duced by 5α-R inhibitors has been raised. Indeed, in FPHL and FFA,
very few side effects or AEs related to sexual function in women treated
with finasteride have been reported (Seale et al., 2016). In agreement,
Mervis and collaborators, by analyzing 24 clinical studies (a total of 521
women), reported a decrease of libido or headache in 1.9% and 2.2% of
cases respectively (Mervis et al., 2018). All these side-effects were
present during the finasteride treatment, but not after its suspension,
suggesting, on the basis of the literature available so far, that PFS is
present only in males.
2. Conclusions and perspectives
As here reported, finasteride or dutasteride treatment in male is
associated with the onset of different side effects (i.e., mainly on sexual
functions as well as on mood, even if other complaints have been de-
scribed). In agreement, rodent models treated with these drugs present
different degree of alterations in sexual function and mood regulation.
Interestingly, some of these side effects has been reported also in fe-
male. On the other hand, reports observing no adverse events have been
published as well, raising doubts about the real presence of such
symptoms and the quality of the studies performed so far.
Another important point, recently emerged, is the persistence of
these side effects after withdrawal of the therapy. This condition,
named as PFS, seems to be present in male patients, with an incidence
on the total population that is still unclear. Results obtained in animal
models confirm the presence of long-term effects of finasteride or du-
tasteride treatment on sexual function and mood, such as depression
and anxiety. However, also in this case, concerns about PFS existence
have been raised. Overall, these data indicate the urgent need to high
quality clinical trials, with long-term follow up, specifically addressing
sexual function and mood disorders. In addition, it is imperative to
study in detail the molecular mechanisms that cause this condition,
trying to identify a possible genetic predisposition, in order to limit the
burden of PFS. Finally, therapeutic strategies, like for instance neu-
roactive steroid treatment, able to relief or to cure this condition are
also urgently needed.
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